CN110772513B - Medicine for treating leukemia - Google Patents
Medicine for treating leukemia Download PDFInfo
- Publication number
- CN110772513B CN110772513B CN201910664791.0A CN201910664791A CN110772513B CN 110772513 B CN110772513 B CN 110772513B CN 201910664791 A CN201910664791 A CN 201910664791A CN 110772513 B CN110772513 B CN 110772513B
- Authority
- CN
- China
- Prior art keywords
- leukemia
- cells
- cell
- compound
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000032839 leukemia Diseases 0.000 title claims abstract description 54
- 239000003814 drug Substances 0.000 title claims abstract description 18
- 229940079593 drug Drugs 0.000 title claims description 11
- 150000001875 compounds Chemical class 0.000 claims abstract description 27
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 25
- 238000011282 treatment Methods 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 6
- 230000035755 proliferation Effects 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 230000009545 invasion Effects 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 229940041181 antineoplastic drug Drugs 0.000 claims description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 2
- 229940034982 antineoplastic agent Drugs 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 190000008236 carboplatin Chemical compound 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- 230000005012 migration Effects 0.000 claims 1
- 238000013508 migration Methods 0.000 claims 1
- 229910052697 platinum Inorganic materials 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 55
- 229920001184 polypeptide Polymers 0.000 abstract description 19
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 19
- 230000000694 effects Effects 0.000 abstract description 17
- 210000004881 tumor cell Anatomy 0.000 abstract description 11
- 230000035699 permeability Effects 0.000 abstract description 9
- 230000006907 apoptotic process Effects 0.000 abstract description 5
- 230000004663 cell proliferation Effects 0.000 abstract description 5
- 230000022534 cell killing Effects 0.000 abstract description 3
- 231100000053 low toxicity Toxicity 0.000 abstract description 2
- 239000012528 membrane Substances 0.000 abstract description 2
- 238000010322 bone marrow transplantation Methods 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 230000001965 increasing effect Effects 0.000 description 11
- 201000010099 disease Diseases 0.000 description 10
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 8
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 8
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 7
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- 206010000830 Acute leukaemia Diseases 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 210000001185 bone marrow Anatomy 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 238000002512 chemotherapy Methods 0.000 description 5
- 208000024207 chronic leukemia Diseases 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000003394 haemopoietic effect Effects 0.000 description 5
- 230000008595 infiltration Effects 0.000 description 5
- 238000001764 infiltration Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000005728 strengthening Methods 0.000 description 4
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 3
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 3
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 3
- 102000004495 STAT3 Transcription Factor Human genes 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 208000007502 anemia Diseases 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 208000014951 hematologic disease Diseases 0.000 description 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 208000018706 hematopoietic system disease Diseases 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000008728 vascular permeability Effects 0.000 description 2
- 239000002525 vasculotropin inhibitor Substances 0.000 description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 208000016557 Acute basophilic leukemia Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 206010014958 Eosinophilic leukaemia Diseases 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010048643 Hypereosinophilic syndrome Diseases 0.000 description 1
- 244000219416 Hypericum japonicum Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000035490 Megakaryoblastic Acute Leukemia Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000005228 Pericardial Effusion Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 description 1
- 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000020700 acute megakaryocytic leukemia Diseases 0.000 description 1
- 208000026784 acute myeloblastic leukemia with maturation Diseases 0.000 description 1
- 208000036676 acute undifferentiated leukemia Diseases 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000719 anti-leukaemic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000021668 chronic eosinophilic leukemia Diseases 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 230000007849 functional defect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 206010019847 hepatosplenomegaly Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000002843 lactate dehydrogenase assay Methods 0.000 description 1
- 206010024378 leukocytosis Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 238000011418 maintenance treatment Methods 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 208000031223 plasma cell leukemia Diseases 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to a medicament for treating leukemia, which particularly comprises a compound and polypeptide, can improve the membrane permeability and the cell killing effect of leukemia cells, has low toxicity to normal cells, can effectively inhibit the cell proliferation of the leukemia cells and induce the apoptosis of tumor cells, and has better application prospect.
Description
Technical Field
The invention relates to a medicine capable of specifically inhibiting leukemia, and belongs to the field of biological pharmacy.
Background
Leukemia (leukemia) is a malignant tumor disease that occurs in hematopoietic organs, with proliferation and dysplasia of leukocytes and their precursor cells in the blood and bone marrow. Due to abnormal differentiation of hematopoietic stem cells, leukemia cells abnormally excessively proliferate in bone marrow and other hematopoietic tissues, accumulate and infiltrate other tissues and organs, and inhibit normal hematopoiesis, and clinically present with symptoms of hemorrhage, anemia, infection and infiltration of various organs.
According to relevant statistics, leukemia accounts for about 3% of the incidence rate of tumors, and is better for children and young people, and male patients are more female than female patients. The incidence of leukemia is highest in countries around the world, both in europe and north america, with a mortality rate of 3.2-7.4 per 10 million people. Asia and south America have low morbidity with mortality rates of 2.8-4.5 per 10 million of the population and increasing at a rate of at least 3-4 million per year. The mortality rates of malignant tumors in the age groups of China are 6 th (male) and 8 th (female), respectively, and the mortality rates of children and children under 35 years old are 1 st.
In recent years, with the rapid development of economy in China, the environmental pollution is increasingly serious, tumors become the first diseases of China threatening the health and life of people, particularly the incidence rate of malignant tumors is continuously increased, and the condition of leukemia is not optimistic.
Leukemia can be classified into acute and chronic types according to the degree of maturation and the natural course of the leukemia cells. Acute leukemia is a malignant clonal hematological disease of hematopoietic stem and progenitor cell origin. Clinically, infection, hemorrhage, anemia and extramedullary tissue and organ infiltration are the main manifestations, and the disease progresses rapidly. The natural course of disease is only weeks to months. They can be generally classified into Acute Myelogenous Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) according to their classification into leukemia cell series.
Chronic leukemia is characterized by hyperproliferation of functional differentiated mature cells, and chronic leukemia is therefore a disease due to poor signaling or uncontrolled cell proliferation, rather than to a failure of maturation. Chronic leukemia is usually chronic myelogenous leukemia (C ML) and Chronic Lymphocytic Leukemia (CLL).
The proliferation and infiltration of leukocytes are the specific pathological changes of leukemia, manifesting as lymphadenectasis, hepatosplenomegaly, and sternal tenderness. It can also be indicated for other infiltrations, such as pleural effusion, peritoneal or pericardial effusion, and central nervous system infiltration. Leukemia causes a decrease in the number and functional defects of neutrophils, which easily causes various bacterial infections, among which inflammation of the oral cavity, the intestine, the lung and the like is the most common. Thrombocytopenia, fibrinolysis, disseminated intravascular coagulation and plasma protein-bound polysaccharide increase, blood coagulation inhibition, and bleeding of patients, which are commonly seen in skin mucosa, hematopoietic tissue, spleen and stomach. The normal differentiated cells of the part produced by leukemia inhibit the normal hematopoietic cells, destroy the bone marrow environment for the growth of red blood cells, cause hemolysis and cause anemia. Leukocytosis can also lead to small vessel occlusion and hemorrhagic embolism, causing paralysis, coma, and even death of the patient.
Chemotherapy is still the main treatment for leukemia, and aims to eliminate leukemia cell clone and rebuild normal hematopoietic function of bone marrow. Acute leukemia treatment can be divided into two phases, induction remission and post-remission treatment (consolidation strengthening and maintenance treatment). The induction remission stage is a combined composition scheme of several different drugs with different mechanisms of action, and the dosage is to achieve the degree of mild inhibition of bone marrow. The medicine is taken for 1-2 courses of treatment to achieve complete relief and restore the hematopoietic function. But at the moment, the patient is not cured, the treatment enters the stage 2, namely post-remission treatment, the post-remission treatment generally begins two weeks after the complete remission is obtained for the first time, the chemotherapy scheme selects a plurality of new schemes besides the original scheme used for inducing the remission, wherein the new schemes comprise two large-dose strengthening schemes which are inserted in the new schemes, and the schemes are alternately and alternately carried out to carry out the strengthening and strengthening treatment.
Radiation therapy is often used as part of a pretreatment regimen in hematopoietic stem cell transplantation, but because the leukemia cells themselves are perfused in the human circulatory system, hematopoietic organs and infiltrated tissues, radiation therapy has certain limitations in leukemia therapy, typically used to locally irradiate significantly enlarged liver and spleen or lymph nodes to relieve symptoms, or used as a pretreatment prior to bone marrow transplantation to reduce rejection.
Bone Marrow Transplantation (BMT) is the treatment of choice currently prevalent in the treatment of leukemia, as bone marrow transplantation is a real method of treating leukemia. The superiority of bone marrow transplantation compared with common chemotherapy is fully reflected in acute leukemia, and the treatment can obviously improve the disease-free survival rate of patients with acute leukemia. According to massive case analysis of Fred Hutchinson cancer research center and IBMTR, the disease-free survival rate of AML can reach about 50% in 3 years after AML receives ALLo-BMT in first remission; while the 3-year disease-free survival rate of patients with concurrent chemotherapy is only 18-27%. BMT efficacy is affected by a number of factors, mainly BMT timing: the efficacy of the first remission of BMT is superior to the second remission period. Brotint et AL (1988) compared the first remission and second remission BMT results in AL patients and found that after the first remission BMT, the 5-year recurrence rate of the patients was 21% + -11% and the 5-year disease-free survival rate was 46% + -9%; the 5-year relapse rate and survival rate of patients after the second remission BMT were 56% and 22%, respectively. Similar results were obtained for the IBMTR and Seattle data. Therefore, patients with acute leukemia are preferably fed BMT in the first complete remission. The nature of the disease itself: the relationship between BMT efficacy and typing is not clear, and AML efficacy is generally considered superior to ALL for ALL patients. Age and general condition of the patient: since the older the age, the poorer the organ function, and the greater the possibility of various complications, particularly GVHD, occurring after BMT, it is prudent to perform allogeneic bone marrow transplantation in patients over 45 years old, and generally not to perform allogeneic bone marrow transplantation over 50 years old.
In recent years, targeted therapy of leukemia cells has become a development trend of leukemia therapy, and targeted killing of leukemia cells by using monoclonal antibodies, cytokines or genes and the like has a good application prospect in clinic and can become another cure means of leukemia.
In the patent field, the application of the compound in the field of treating leukemia is also wide. For example, CN102961374B discloses an application of a compound shown in formula I in preparation of a STAT3 inhibitor and a STAT3 inhibitor, the compound shown in formula I can obviously inhibit proliferation and survival of various tumor cells such as acute and chronic leukemia, multiple myeloma, lymphoma, lung cancer, prostate cancer, cervical cancer and the like, inhibit a STAT3 signal channel of the tumor cells, activate relevant factors for inducing apoptosis of the tumor cells, thereby inducing apoptosis of the tumor cells and achieving the effect of treating tumor diseases.
CN103751172B discloses the application of dixanthone compounds in the preparation of anti-leukemia drugs, and also includes a method for extracting 5 dixanthone compounds from hypericum japonicum medicinal materials. Leukemia cell activity experiments are carried out on the 5 natural dixanthone compounds, and results show that the 5 dixanthone compounds have inhibitory activity on leukemia cells K562, HL-60 and THP-1, and have better inhibitory activity on K562 cells. The 5 dixanthone compounds exert antitumor activity through BCL2 protein family, and according to the result of a leukemia solid tumor nude mouse model, the growth of tumors can be inhibited, and the life cycle of the tumor model can be prolonged.
CN100441222C discloses the application of compound PS-341 in the preparation of medicine for treating M2 type acute saccharic leukemia with t (8; 21) chromosome translocation. Solves the problems that most patients can obtain remission, but relapse quickly and gradually generate drug resistance to cause treatment failure and the drugs have large toxic and side effects because the existing AML M2 treatment mainly treats the chemotherapy of large dose of cytarabine combined with daunorubicin or desmethoxyrubicin.
In recent years, there have been studies showing that low concentrations of VEGF in normal humans are mainly associated with angiogenesis, and that malignant hematological diseases also have angiogenesis. Under the condition that VEGF in tumor cells is over-expressed, the concentration of VEGF in local tumor tissues is abnormally increased, the cardiovascular production is further promoted, nutrients are increased for the tumor cells, the growth and proliferation of the tumor cells are further promoted, and the method is also greatly related to the invasion and metastasis of the tumor cells. By comparing the serum VEGF expression level before the leukemia patient is treated with the serum VEGF expression level of a reference group, the VEGF expression level in the serum of the leukemia patient is far higher than that of a healthy population, and the VEGF expression level in the serum of the leukemia patient after the leukemia patient is subjected to standardized treatment is far lower than that before the leukemia patient is treated. VEGF has the main biological function of increasing vascular permeability, is a main induction factor for promoting cardiovascular generation, can stimulate endothelial cells to cause hyperproliferation of endothelial cells so as to promote neoangiogenesis, and deposits a large amount of fibrinogen in an extravascular matrix under the condition of increasing vascular permeability, so that nutrients are further provided for vascular production and tumor cell growth, and necessary conditions are provided for further invasion and metastasis of tumors. Therefore, the VEGF inhibitor has better application value in treating leukemia patients by using the VEGF inhibitor.
However, in these applications, the toxic effect of the compound is strong, and the compound is also lovely and lovely killed to human body while treating leukemia, so the inventor improves on the basis of the above, and provides a novel pharmaceutical composition for treating leukemia, which can reduce the toxicity of the compound and improve the inhibition effect.
Disclosure of Invention
There is still room for improvement in therapeutic effects of the drugs studied earlier by the inventors.
The invention aims to provide a compound and preparation and application thereof. The compound provided by the invention has a structure shown in formula 1, can effectively inhibit the growth of K562 leukemia cells, and has a good application prospect.
In another aspect of the present invention, there is provided a polypeptide capable of increasing the permeability of leukemia cell membrane, such as SEQ ID NO: 1 is shown. The polypeptide can obviously improve the permeability of K562 leukocyte cell membranes, improve cell leakage and inhibit cell growth.
Permeation peptide SEQ ID NO: 1:
in another aspect of the present invention, there is provided a composition comprising SEQ ID NO: 1 in combination with a compound of formula 1, a synergistically enhanced cell killing effect is achieved.
The invention also provides an antitumor drug composition, which is a common preparation in pharmacy prepared by taking the compound, the polypeptide and the pharmaceutically acceptable salt thereof as active ingredients and adding pharmaceutically acceptable auxiliary materials or auxiliary ingredients.
The compounds and polypeptides of the invention may be formulated for administration either alone or in combination with one or more acceptable carriers. Such as solvents, diluents, and the like. Can be administered in oral dosage forms, such as tablet, capsule, dispersible powder, granule, etc.; can also be administered by injection, such as lyophilized powder for injection. The various dosage forms of the pharmaceutical compositions of the present invention may be prepared according to methods well known in the pharmaceutical art. These pharmaceutical preparations may contain, in combination with a carrier, for example
Weight active ingredient, more usually about
Active ingredient in between. The dosage of the compounds and polypeptides of the present invention may be varied beyond this range depending on the severity of the disease or the dosage form.
The leukemia refers to acute myelogenous leukemia, chronic myelogenous leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, acute nonlymphocytic leukemia, chronic leukemia, plasma cell leukemia, chronic myelogenous leukemia, eosinophilic leukemia, basophilic leukemia, megakaryocytic leukemia, undifferentiated acute leukemia or histiophilic leukemia, and low-proliferative leukemia type drug-resistant leukemia.
Advantageous effects
Due to the application of the technical scheme, compared with the prior art, the invention has the following advantages:
the invention discloses the synergistic effect of the compound and the polypeptide for the first time, improves the membrane permeability and the cell killing effect of leukemia cells, has low toxicity to normal cells, can effectively inhibit the cell proliferation of the leukemia cells and induce the apoptosis of tumor cells, and has better application prospect.
Obviously, many modifications, substitutions, and variations are possible in light of the above teachings of the invention, without departing from the basic technical spirit of the invention, as defined by the following claims.
The present invention will be described in further detail with reference to the following examples. This should not be understood as limiting the scope of the above-described subject matter of the present invention to the following examples. All the technologies realized based on the above contents of the present invention belong to the scope of the present invention.
Description of the drawings:
FIG. 1: cell culture time versus cell density.
Detailed Description
EXAMPLE 1 culture of cells and preparation of polypeptide
Tumor cell lines: the K562 leukemia cells (preserved in Shanxi province national hospital blood disease research room) are recovered from liquid nitrogen, and then the K562 leukemia cells are placed in RPMI-1640 culture solution containing 10% inactivated fresh calf serum, and the volume fraction is 5% CO at 37 DEG C2Culturing under saturated humidity condition, keeping cell activity > 97%, and collecting K562 cell (1) in exponential growth phaseX105Pieces/ml) are divided into a control group and an experimental group for later use.
The nucleotide sequence of SEQ ID NO: 1, is obtained by a synthesis method and is completed by Beijing Yi Qiao Shenzhou science and technology Co.
Example 2 Lactate Deaminase (LDH) Release assay for cell Membrane permeability assay
At 5X103Density of individual cells/well K562 cells were added to 96-well plates for culture. The polypeptide (SEQ ID NO: 1 at pH 7.5) was incubated with the cells for 2 hours. LDH concentration (LDHsample) was determined using a chromogenic LDH kit. Triton-X100 (0.2% final concentration) was added to some wells to prepare cell lysates. LDH concentration in cell lysates was defined as LDHtotal. The release of LDH (ldhreease) was calculated according to the following formula:
LDHrelease＝100％X(LDHsample/LDHtotal)
cell viability assays were performed on the same cells after all supernatants were removed for LDH release assays. Cell activity values and LDH release values are listed in table 1. As can be seen from table 1, LDH release increased with increasing polypeptide concentration after polypeptide treatment of cells. The release of LDH is generally used as a measure of the permeability of cell membranes and results show that polypeptides increase cell permeability and thus lead to a decrease in cell activity.
TABLE 1 relationship between cellular Activity and LDH Release
| Polypeptide (mu M) | 0 | 10 | 20 | 40 | 80 |
| Cell Activity (%) | 100 | 80.3 | 31.2 | 21.5 | 11.3 |
| LDH Release (%) | 2.56 | 32.5 | 51.4 | 63.8 | 76.9 |
The above results indicate that LDH release is directly related to a decrease in cellular activity after the polypeptide has acted on the cells. Normal cells release approximately 1-5% of LDH to the outside. The release of LDH increases with increasing polypeptide concentration after the polypeptide acts on the cell. Since LDH release is commonly used to measure cell membrane permeability, the results show that SEQ ID NO: 1 results in increased cell permeability and decreased cellular activity.
Example 3 cell proliferation inhibition assay
Cell proliferation inhibition assay: k562 cells in logarithmic growth phase were added at 1 × 105/mL to 24-well plates at 1 μ L per well with 80 μ M peptide group, 80 μ M peptide +20 μ M compound drug group of formula 1, PBS blank control group, counted after 12, 24, 36, 48h, viable cells counted using trypan blue exclusion experiment, the experiment was repeated 3 times, averaged, and the growth curve was plotted, as shown in fig. 1.
As can be seen from FIG. 1, the polypeptide and the compound of formula 1 taken alone have similar inhibitory effect on cells and have certain effect, and the polypeptide and the compound of formula 1 taken together can obviously inhibit the cellsCell proliferation and cell apoptosis promotion, cell survival rate is less than 1% at 48h, and cell density is reduced to 0.001 x105And (4) the compound shows excellent inhibition effect per ml.
Example 4 cytotoxicity assay
293T cells, 16HBE cells and WI-38[ WI38 ]]Culturing human embryo lung fibroblast cells by conventional culture method, and collecting cells with concentration of 1X105And (4) respectively. 5X103The density of each cell/well will be 293T cells, 16HBE cells and WI-38[ WI38]Human embryonic lung fibroblasts were added to a 96-well plate and the polypeptide + compound of formula 1 mixture was added and incubated with the cells for 4 hours, with no drug in PBS as a control. The cell density detection shows that the cell density of the control group is basically the same as that of the drug-added group, which shows that the composition provided by the invention has no obvious killing effect on normal cells and has better application prospect.
Although the invention has been described in detail with respect to the general description and the specific embodiments, it will be apparent to those skilled in the art that modifications and improvements can be made based on the invention. Accordingly, it is intended that all such modifications and variations as fall within the true spirit of this invention be included within the scope thereof.
Claims (8)
1, SEQ ID NO: 1 and application of compound of formula 1 in preparation of medicament for treating leukemia
2. Use according to claim 1, characterized in that: wherein the dosage ratio of the medicines is as follows: 80 μ M of the cell membrane-penetrating peptide was used in combination with 20 μ M of the compound of formula 1.
3. Use according to claim 2, characterized in that: other medicines for inhibiting the migration, invasion and proliferation of the leukemia cells are also added.
4. Use according to any one of claims 2 to 3, characterized in that: comprises pharmaceutically acceptable auxiliary materials which are compounded to prepare the medicinal composition.
5. The use of claim 3, wherein the medicament comprises a platinum antineoplastic agent.
6. The use according to claim 5, wherein the antineoplastic drug is cisplatin or carboplatin.
7. A cell membrane-permeable peptide, the sequence of which is as shown in SEQ ID NO: 1 is shown.
8. Use of the cell membrane-penetrating peptide of claim 7 for the preparation of a medicament for the treatment of leukemia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910664791.0A CN110772513B (en) | 2019-07-15 | 2019-07-15 | Medicine for treating leukemia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910664791.0A CN110772513B (en) | 2019-07-15 | 2019-07-15 | Medicine for treating leukemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110772513A CN110772513A (en) | 2020-02-11 |
| CN110772513B true CN110772513B (en) | 2021-06-22 |
Family
ID=69383852
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910664791.0A Expired - Fee Related CN110772513B (en) | 2019-07-15 | 2019-07-15 | Medicine for treating leukemia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110772513B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013123071A1 (en) * | 2012-02-13 | 2013-08-22 | Cleave Biosciences, Inc. | Methods and compositions for jamm protease inhibition |
| CN104606189A (en) * | 2015-01-08 | 2015-05-13 | 苏州大学 | Application of compound to preparation of mTOR inhibitor |
| CN109865125A (en) * | 2019-03-05 | 2019-06-11 | 陕西省人民医院 | It adjusts peptide and mansonone E and treats improved leukemia medicament and application thereof in preparation |
-
2019
- 2019-07-15 CN CN201910664791.0A patent/CN110772513B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013123071A1 (en) * | 2012-02-13 | 2013-08-22 | Cleave Biosciences, Inc. | Methods and compositions for jamm protease inhibition |
| CN104606189A (en) * | 2015-01-08 | 2015-05-13 | 苏州大学 | Application of compound to preparation of mTOR inhibitor |
| CN109865125A (en) * | 2019-03-05 | 2019-06-11 | 陕西省人民医院 | It adjusts peptide and mansonone E and treats improved leukemia medicament and application thereof in preparation |
Non-Patent Citations (3)
| Title |
|---|
| Inhibition of cancer cell proliferation by designed peptide amphiphiles;Lorenzo Aulisa等;《Acta Biomaterialia》;20081127;第5卷(第3期);第842-853页 * |
| The Anti-Cancer Peptide, PNC-27, Induces Tumor Cell Necrosis of a Poorly Differentiated Non-Solid Tissue Human Leukemia Cell Line that Depends on Expression of HDM-2 in the Plasma Membrane of these Cells;Katlin Davitt等;《Annals of Clinical & Laboratory Science》;20141231;第44卷(第3期);第241-248页 * |
| 靶向多肽R8-HBAP抑制成人T细胞;宋早文等;《浙江师范大学学报（自然科学版）》;20180531;第41卷(第2期);第74-80页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110772513A (en) | 2020-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107375258A (en) | A kind of antineoplastic combination medicine and its purposes in cancer therapy drug is prepared | |
| CN113694085A (en) | Application of slug extract in preparation of combined medicine for cancer chemotherapy scheme | |
| CN105380956B (en) | A kind of pharmaceutical composition of Dana Delany containing Chinese mugwort for treating leukaemia and application | |
| CN110772513B (en) | Medicine for treating leukemia | |
| CN115521385B (en) | Armillarisin mycelium polysaccharide, preparation method thereof and application thereof in resisting tumors | |
| TWI606835B (en) | Reishi polysaccharide-based compositions and methods for treatment of cancer | |
| CN108295085B (en) | Application of protodioscin in preparation of drug-resistant osteosarcoma drug | |
| CN102688228B (en) | Pharmaceutical composition containing apigenin, apigenin derivative, rubescensin and rubescensin derivative, and application thereof | |
| CN107693790B (en) | Combination for the treatment of lung cancer | |
| CN111821319A (en) | Application of periplaneta americana extract CII-3 in toxicity-reducing and synergistic antitumor drug cisplatin | |
| CN113893338A (en) | Application of CD38 CAR-T cells in acute myelopathy of chronic myelocytic leukemia | |
| WO2020098329A1 (en) | Antrodia cinnamomea extract, method for preparing antrodia cinnamomea composition, and pharmaceutical composition | |
| CN113209149A (en) | Application of mitoxantrone and total ginsenoside combined medicine in preparation of medicine for treating gastric cancer | |
| CN108721268B (en) | Compound pharmaceutical composition with anti-lymphoma effect and application thereof | |
| CN112843052B (en) | Application of epigenetic factor inhibitor 2800Z in preparation of liver cancer resistant drug sensitizer | |
| CN111544479B (en) | Application of pharmaceutical composition in preparation of medicines for treating cancers | |
| CN109419792A (en) | It is a kind of to treat gastric cancer compound | |
| CN111840523B (en) | An anticancer pharmaceutical composition containing active protein and active fatty acid | |
| CN114129561B (en) | Application of artemisinin drugs in preparation of drugs for preventing and treating recurrence and metastasis after tumor resection | |
| CN111249298B (en) | Anticancer pharmaceutical composition containing maduramicin and cisplatin | |
| CN111544580B (en) | Anti-cancer pharmaceutical composition | |
| CN110876803B (en) | Pharmaceutical composition containing milk protein and oleic acid | |
| CN103417542B (en) | Oral solid preparation for treatment of leukemia and application thereof | |
| CN110123825B (en) | Pharmaceutical composition containing demethoxydaunorubicin | |
| CN110935027B (en) | Pharmaceutical composition of arsenic trioxide and FLT3 inhibitor and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20210622 |